Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose cotransporter...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Circulation (New York, N.Y.) Ročník 145; číslo 19; s. 1460
Hlavní autoři:	Neuen, Brendon L, Oshima, Megumi, Agarwal, Rajiv, Arnott, Clare, Cherney, David Z, Edwards, Robert, Langkilde, Anna Maria, Mahaffey, Kenneth W, McGuire, Darren K, Neal, Bruce, Perkovic, Vlado, Pong, Annpey, Sabatine, Marc S, Raz, Itamar, Toyama, Tadashi, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zinman, Bernard, Heerspink, Hiddo J L
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.05.2022
Témata:	Antihypertensive Agents - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Glucose Humans Hyperkalemia - chemically induced Hyperkalemia - epidemiology Hypokalemia - chemically induced Hypokalemia - epidemiology Male Mineralocorticoid Receptor Antagonists - adverse effects Potassium Randomized Controlled Trials as Topic Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - epidemiology Sodium Sodium-Glucose Transporter 2 Inhibitors - adverse effects heart failure sodium-glucose transporter 2 inhibitors potassium type 2 renal insufficiency hyperkalemia diabetes mellitus chronic
ISSN:	1524-4539, 1524-4539
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!